Biotech receives worldwide licensing rights to web tool for CRISPR efficiency, TIDE

The Netherlands Cancer Institute (NKI) has granted exclusive worldwide licensing rights for its web tool, TIDE — Tracking of Indels by DEcomposition — to biotech company, Desktop Genetics (DTG).

TIDE is a tool that calculates the efficiency of CRISPR using Sanger DNA sequencing and will enable investigators to quantitatively assess genome editing on the DESKGEN Cloud software from DTG. TIDE will be added to the software platform offering users a full end-to-end CRISPR software solution from design to analysis, streamlining the planning and execution of experiments by allowing all relevant data to be stored in one place.

Professor Bas van Steensel, PhD Professor and Group Leader at NKI, commented: “This collaboration is a great opportunity for both parties as it allows TIDE to be managed and to grow in an environment of synergistic design tools, developed by an outstanding team. With this collaboration, TIDE could reach more scientists around the world, gain new functionality and continue to support ground-breaking CRISPR-enabled research.”

“We are proud to integrate TIDE into the DESKGEN platform,” said Victor Dillard, COO at DTG. “This is a natural addition for our users and we look forward to expanding the capabilities of TIDE alongside our own DESKGEN artificial intelligence capabilities.”

Riley Doyle, CEO at DTG added: “The free tools we offer allow scientists to efficiently store and manage their experiments, which could save them hours. We look to continue providing a one-stop platform for accurate and reproducible CRISPR investigation design for academic and private institutions, alike.”

The partnership will enable customers of NKI and Desktop Genetics to access the TIDE tool regardless of where they originally signed up.